1.Mental health-related presentations to a tertiary emergency department during the COVID-19 pandemic.
Elijah Gin LIM ; Ashley Ern Hui HOW ; Julian Zhong Hui LEE ; Sameera GANTI ; Eunizar OMAR
Singapore medical journal 2025;66(12):645-650
INTRODUCTION:
The coronavirus disease 2019 (COVID-19) pandemic has caused significant mental distress in populations globally. At the frontline of the pandemic, emergency departments (EDs) are the prime setting to observe the effects of the pandemic on the mental health of the population. We aimed to describe the trend of mental health-related ED attendances at an acute hospital in Singapore before and during the various stages of the COVID-19 pandemic.
METHODS:
This is a retrospective, descriptive study of patients who presented to the ED between 1 January 2019 and 31 December 2020. Patients diagnosed with mental health-related systematised nomenclature of medicine who visited the ED during this period were identified and were placed into mental health diagnosis categories for analysis. A comparison was made between patients who presented before the pandemic (2019) and during the pandemic (2020).
RESULTS:
During the study periods, we identified 1,421 patients, of whom 27 were excluded due to non-mental health-related diagnoses, leaving 1,394 patients for analysis. There was a 36.7% increase in mental health-related ED presentations from 2019 to 2020. The proportion of higher-acuity mental health-related ED attendances and number of suicide attempts also increased.
CONCLUSION
Our study described an increase in the proportion of high-acuity mental health-related ED attendances during the COVID-19 pandemic. Emergency physicians must be cognisant of the effects of the pandemic on mental health. Further research should be conducted to better equip the healthcare system for handling all aspects of the pandemic.
Humans
;
COVID-19/psychology*
;
Emergency Service, Hospital/statistics & numerical data*
;
Retrospective Studies
;
Singapore/epidemiology*
;
Male
;
Female
;
Adult
;
Middle Aged
;
Mental Disorders/diagnosis*
;
Mental Health
;
SARS-CoV-2
;
Tertiary Care Centers
;
Pandemics
;
Aged
;
Suicide, Attempted/statistics & numerical data*
;
Young Adult
;
Adolescent
3.Singapore clinical guideline on parenteral nutrition in adult patients in the acute hospital setting.
Johnathan Huey Ming LUM ; Hazel Ee Ling YEONG ; Pauleon Enjiu TAN ; Ennaliza SALAZAR ; Tingfeng LEE ; Yunn Cheng NG ; Janet Ngian Choo CHONG ; Pay Wen YONG ; Jeannie Peng Lan ONG ; Siao Ching GOOI ; Kristie Huirong FAN ; Weihao CHEN ; Mei Yoke LIM ; Kon Voi TAY ; Doris Hui Lan NG
Annals of the Academy of Medicine, Singapore 2025;54(6):350-369
INTRODUCTION:
The primary objective of this guideline is to establish evidence-based recommendations for the clinical use of parenteral nutrition (PN) in adult patients within the acute hospital setting in Singapore.
METHOD:
An expert workgroup, consisting of healthcare practitioners actively involved in clinical nutrition support across all public health institutions, systematically evaluated existing evidence and addressed clinical questions relating to PN therapy.
RESULTS:
This clinical practice guideline developed 30 recommendations for PN therapy, which cover these key aspects related to PN use: indications, patient assess-ment, titration and formulation of PN bags, access routes and devices, and monitoring and management of PN-related complications.
CONCLUSION
This guideline provides recommendations to ensure appropriate and safe clinical practice of PN therapy in adult patients within the acute hospital setting.
Humans
;
Singapore
;
Parenteral Nutrition/adverse effects*
;
Adult
4.Novel carbazole attenuates vascular remodeling through STAT3/CIAPIN1 signaling in vascular smooth muscle cells.
Joo-Hui HAN ; Jong-Beom HEO ; Hyung-Won LEE ; Min-Ho PARK ; Jangmi CHOI ; Eun Joo YUN ; Seongpyo LEE ; Gyu Yong SONG ; Chang-Seon MYUNG
Acta Pharmaceutica Sinica B 2025;15(3):1463-1479
This study investigated the molecular mechanism of phenotypic switching of vascular smooth muscle cells (VSMCs), which play a crucial role in vascular remodeling using 9H-Carbazol-3-yl 4-aminobenzoate (CAB). CAB significantly attenuated platelet-derived growth factor (PDGF)-induced VSMC proliferation and migration. CAB suppressed PDGF-induced STAT3 activation by directly binding to the SH2 domain of STAT3. Downregulation of STAT3 phosphorylation by CAB attenuated CIAPIN1/JAK2/STAT3 axis through a decrease in CIAPIN1 transcription. Furthermore, abrogated CIAPIN1 decreased KLF4-mediated VSMC dedifferentiation and increased CDKN1B-induced cell cycle arrest and MMP9 suppression. CAB inhibited intimal hyperplasia in injury-induced neointima animal models by inhibition of the CIAPIN1/JAK2/STAT3 axis. However, CIAPIN1 overexpression attenuated CAB-mediated suppression of VSMC proliferation, migration, phenotypic switching, and intimal hyperplasia. Our study clarified the molecular mechanism underlying STAT3 inhibition of VSMC phenotypic switching and vascular remodeling and identified novel active CAB. These findings demonstrated that STAT3 can be a major regulator to control CIAPIN1/JAK2/STAT3 axis that may be a therapeutic target for treating vascular proliferative diseases.
5.Use of Pulmonary Rehabilitation for Lung Cancer Patients in Korea:Analysis of the National Health Insurance Service Database
Sang Hun KIM ; Cho Hui HONG ; Jong-Hwa JEONG ; Jinmi KIM ; Jeong Su CHO ; Jin A YOON ; Jung Seop EOM ; Byeong Ju LEE ; Myung Hun JANG ; Myung-Jun SHIN ; Yong Beom SHIN
Journal of Korean Medical Science 2025;40(17):e150-
This study aimed to assess the utilization trends of pulmonary rehabilitation (PR) among lung cancer patients in Korea using the National Health Insurance Service (NHIS) database (2017 to 2021). PR was introduced and covered under the NHIS in 2016, primarily for chronic obstructive pulmonary disease, but recent evidence suggests its benefits for lung cancer patients. Data extraction was based on Korea Informative Classification of Diseases 8th revision codes C33 and C34, with PR prescriptions identified by codes MM440 and MM290.Descriptive statistical analysis was performed, and propensity score matching was used for comparison between PR and non-PR groups. Results showed a significant increase in PR utilization, with the number of patients receiving PR (MM440) rising from 1,002 in 2017 to 3,723 in 2021, indicating a 3.7-fold increase. However, the proportion of patients receiving PR remained low at 2.9% in 2021. Enhanced access to PR services and improved evaluation strategies are essential for optimizing patient outcomes.
6.Use of Pulmonary Rehabilitation for Lung Cancer Patients in Korea:Analysis of the National Health Insurance Service Database
Sang Hun KIM ; Cho Hui HONG ; Jong-Hwa JEONG ; Jinmi KIM ; Jeong Su CHO ; Jin A YOON ; Jung Seop EOM ; Byeong Ju LEE ; Myung Hun JANG ; Myung-Jun SHIN ; Yong Beom SHIN
Journal of Korean Medical Science 2025;40(17):e150-
This study aimed to assess the utilization trends of pulmonary rehabilitation (PR) among lung cancer patients in Korea using the National Health Insurance Service (NHIS) database (2017 to 2021). PR was introduced and covered under the NHIS in 2016, primarily for chronic obstructive pulmonary disease, but recent evidence suggests its benefits for lung cancer patients. Data extraction was based on Korea Informative Classification of Diseases 8th revision codes C33 and C34, with PR prescriptions identified by codes MM440 and MM290.Descriptive statistical analysis was performed, and propensity score matching was used for comparison between PR and non-PR groups. Results showed a significant increase in PR utilization, with the number of patients receiving PR (MM440) rising from 1,002 in 2017 to 3,723 in 2021, indicating a 3.7-fold increase. However, the proportion of patients receiving PR remained low at 2.9% in 2021. Enhanced access to PR services and improved evaluation strategies are essential for optimizing patient outcomes.
7.Clinical practice guidelines for cervical cancer: an update of the Korean Society of Gynecologic Oncology Guidelines
Ji Geun YOO ; Sung Jong LEE ; Eun Ji NAM ; Jae Hong NO ; Jeong Yeol PARK ; Jae Yun SONG ; So-Jin SHIN ; Bo Seong YUN ; Sung Taek PARK ; San-Hui LEE ; Dong Hoon SUH ; Yong Beom KIM ; Keun Ho LEE
Journal of Gynecologic Oncology 2025;36(1):e70-
We describe the updated Korean Society of Gynecologic Oncology (KSGO) practice guideline for the management of cervical cancer, version 5.1. The KSGO announced the fifth version of its clinical practice guidelines for the management of cervical cancer in March 2024. The selection of the key questions and the systematic reviews were based on data available up to December 2022. Between 2023 and 2024, substantial findings from large-scale clinical trials and new advancements in cervical cancer research remarkably emerged. Therefore, based on the existing version 5.0, we updated the guidelines with newly accumulated clinical data and added 4 new key questions reflecting the latest insights in the field of cervical cancer. For each question, recommendation was formulated with corresponding level of evidence and grade of recommendation, all established through expert consensus.
8.Diagnostic performance of various radiological modalities in the detection of sarcopenia within Asian populations: a systematic review
Shi Wei ANG ; Jacqueline LIEW ; Vanessa Malishree DHARMARATNAM ; Vanessa Yi Jean YIK ; Shawn KOK ; Syed AFTAB ; Cherie TONG ; Hui Bing LEE ; Shimin MAH ; Clement YAN ; Bin-Tean TEH ; Frederick H. KOH
Annals of Coloproctology 2025;41(1):27-39
Purpose:
Diagnosing sarcopenia necessitates the measurement of skeletal muscle mass. However, guidelines lack a standardized imaging modality with thresholds validated among Asians. This systematic review compared ultrasonography, computed tomography (CT), magnetic resonance imaging (MRI), and bioelectrical impedance analysis (BIA)/body composition monitoring in the detection of sarcopenia within Asian populations.
Methods:
PubMed and Embase were systematically searched for studies analyzing ultrasonography, CT, MRI, and BIA in diagnosing sarcopenia among Asians. Study quality was assessed using the Newcastle-Ottawa scale.
Results:
Pooled findings from 21,598 patients across 25 studies were examined. In receiver operating characteristic analysis, ultrasound displayed a pooled mean area under the curve (AUC) of 0.767 (95% confidence interval [CI], 0.709–0.806), with mean sensitivity of 81.1% (95% CI, 0.744–0.846) and specificity of 73.1% (95% CI, 0.648–0.774), for detecting sarcopenia in Asian populations. CT exhibited an AUC of 0.720 (sensitivity, 54.0%; specificity, 92.0%). MRI demonstrated an AUC of 0.839 (sensitivity, 67.0%; specificity, 66.0%). BIA displayed an AUC of 0.905 (95% CI, 0.842–0.968), 80.7% sensitivity (95% CI, 0.129–0.679), and 82.4% specificity (95% CI, 0.191–0.633).
Conclusion
Various modalities aid in diagnosing sarcopenia, and selection should be individualized. Although only BIA and dual-energy x-ray absorptiometry are recommended by the Asian Working Group for Sarcopenia and the European Working Group on Sarcopenia in Older People, ultrasound imaging may hold diagnostic value for sarcopenia in the Asian population. In certain groups, diagnostic use of CT and MRI is warranted. Future research can standardize and validate modality-specific thresholds and protocols within Asian populations.
9.Diagnostic performance of various radiological modalities in the detection of sarcopenia within Asian populations: a systematic review
Shi Wei ANG ; Jacqueline LIEW ; Vanessa Malishree DHARMARATNAM ; Vanessa Yi Jean YIK ; Shawn KOK ; Syed AFTAB ; Cherie TONG ; Hui Bing LEE ; Shimin MAH ; Clement YAN ; Bin-Tean TEH ; Frederick H. KOH
Annals of Coloproctology 2025;41(1):27-39
Purpose:
Diagnosing sarcopenia necessitates the measurement of skeletal muscle mass. However, guidelines lack a standardized imaging modality with thresholds validated among Asians. This systematic review compared ultrasonography, computed tomography (CT), magnetic resonance imaging (MRI), and bioelectrical impedance analysis (BIA)/body composition monitoring in the detection of sarcopenia within Asian populations.
Methods:
PubMed and Embase were systematically searched for studies analyzing ultrasonography, CT, MRI, and BIA in diagnosing sarcopenia among Asians. Study quality was assessed using the Newcastle-Ottawa scale.
Results:
Pooled findings from 21,598 patients across 25 studies were examined. In receiver operating characteristic analysis, ultrasound displayed a pooled mean area under the curve (AUC) of 0.767 (95% confidence interval [CI], 0.709–0.806), with mean sensitivity of 81.1% (95% CI, 0.744–0.846) and specificity of 73.1% (95% CI, 0.648–0.774), for detecting sarcopenia in Asian populations. CT exhibited an AUC of 0.720 (sensitivity, 54.0%; specificity, 92.0%). MRI demonstrated an AUC of 0.839 (sensitivity, 67.0%; specificity, 66.0%). BIA displayed an AUC of 0.905 (95% CI, 0.842–0.968), 80.7% sensitivity (95% CI, 0.129–0.679), and 82.4% specificity (95% CI, 0.191–0.633).
Conclusion
Various modalities aid in diagnosing sarcopenia, and selection should be individualized. Although only BIA and dual-energy x-ray absorptiometry are recommended by the Asian Working Group for Sarcopenia and the European Working Group on Sarcopenia in Older People, ultrasound imaging may hold diagnostic value for sarcopenia in the Asian population. In certain groups, diagnostic use of CT and MRI is warranted. Future research can standardize and validate modality-specific thresholds and protocols within Asian populations.
10.Clinical practice guidelines for cervical cancer: an update of the Korean Society of Gynecologic Oncology Guidelines
Ji Geun YOO ; Sung Jong LEE ; Eun Ji NAM ; Jae Hong NO ; Jeong Yeol PARK ; Jae Yun SONG ; So-Jin SHIN ; Bo Seong YUN ; Sung Taek PARK ; San-Hui LEE ; Dong Hoon SUH ; Yong Beom KIM ; Keun Ho LEE
Journal of Gynecologic Oncology 2025;36(1):e70-
We describe the updated Korean Society of Gynecologic Oncology (KSGO) practice guideline for the management of cervical cancer, version 5.1. The KSGO announced the fifth version of its clinical practice guidelines for the management of cervical cancer in March 2024. The selection of the key questions and the systematic reviews were based on data available up to December 2022. Between 2023 and 2024, substantial findings from large-scale clinical trials and new advancements in cervical cancer research remarkably emerged. Therefore, based on the existing version 5.0, we updated the guidelines with newly accumulated clinical data and added 4 new key questions reflecting the latest insights in the field of cervical cancer. For each question, recommendation was formulated with corresponding level of evidence and grade of recommendation, all established through expert consensus.

Result Analysis
Print
Save
E-mail